Biotop-report 2012

Biotech Networks

 

k

BioTOP Berlin-Brandenburg

 

k

BioHyTec Network for Biohybrid Technologies

 

k

BioResponse

 

k

Center for Molecular Diagnostics and Bioanalytics (ZMDB)

 

k

DiagnostikNet-BB

 

k

GABI – Genome Analysis in the Plant Biological System

 

k

NetDDD Network for Drug Discovery & Development Berlin-Brandenburg

 

k

Network Glycobiotechology Berlin-Brandenburg

 

k

Nutrigenomics Network Berlin-Brandenburg

 

k

Regenerative Medicines Initiative Berlin-Brandenburg

 

k

RiNA Network for RNA Technologies

 

Scientific Institutions

 

k

Berlin-Brandenburg Center for Regenerative Therapies

 

k

Berlin Institute of Technology

 

k

Brandenburg University of Technology

 

k

Charité – Universitätsmedizin Berlin

 

k

Fraunhofer Institute for Applied Polymer Research

 

k

Fraunhofer Institute for Biomedical Engineering (IBMT)

 

k

Freie Universität Berlin

 

k

German Heart Instiute Berlin

 

k

German Institute of Human Nutrition (DIfE)

 

k

German Rheumatism Research Center (DRFZ)

 

k

Humboldt-Universität zu Berlin

 

k

Institute of Polymer Research of the GKSS Research Centre

 

k

Lausitz University of Applied Sciences

 

k

Leibniz-Institute for Agricultural Engineering Potsdam-Bornim (ATB)

 

k

Leibniz-Institut für Molekulare Pharmakologie (FMP)

 

k

Leibniz-Zentrum für Agrarlandschaftsforschung (ZALF) e. V.

 

k

Max Delbrück Center for Molecular Medicine (MDC) Berlin-Buch

 

k

Max-Planck-Institute for Colloids and Interfaces

 

k

Max Planck Institute for Infection Biology

 

k

Max Planck Institute for Molecular Genetics

 

k

Max Planck Institute of Molecular Plant Physiology

 

k

Robert Koch Institute

 

k

University of Applied Sciences Berlin

 

k

University of Applied Sciences Wildau

 

k

University of Potsdam

36

BioTOPics 44 | May 2012 

BioTOP-Report

P

 

Bioparks

P

 

Networks 

P

 

Scientific Institutions

P

 Companies

---

37

BioTOPics 44 | May 2012 

BioTOP-Report 

FH

I I

---

caprotec bioanalytics GmbH 

caprotec bioanalytics GmbH has developed 

a ground-breaking, proprietary technology 

to reduce the complexity of protein mixtures 

in a targeted and directed manner. 

Founded in 2006 by scientist and entrepre-

neur Prof. Dr. Hubert Köster, founder of 

Sequenom Inc. and Biosyntech, caprotec 

raised since 2007 approx. 11 million Euro. 

Caprotec is operational in Berlin Adlershof 

since September of 2008 and currently has 

26 employees. 

caprotec’s Capture Compound Mass Spec-

trometry (CCMS) Technology is based on 

multifunctional small molecules that are 

used to target, capture, and isolate proteins 

based on their function. The company is 

commercializing the CCMS technology as 

kits for research applications and in the form 

of interactive research collaborations with 

the pharmaceutical, biotech and agrobio-

chemical industry. In collaborations for drug 

development caprotec is using small mole-

cule drugs or drug candidates to establish a 

profile of proteins that interact specifically 

with the small molecule drug in a mixture of 

human proteins. The profile can be used to 

elucidate the mode of action of drugs and 

drug candidates and also to discover off-tar-

get proteins that potentially could cause 

adverse side effects in humans, e.g. liver 

toxicity.

Address

caprotec bioanalytics GmbH 

Volmerstraße 5 · 12489 Berlin · Germany

Contact

caprotec bioanalytics GmbH

Phone [phone]

[e-mail] · www.caprotec.com

CCMS profiles small molecule interactions with the proteome

Sorting function

(isolates drug/molecule‘s specific 

binding partners)

Photoreactivity function

(captures protein binding partners)

Selectivity function

(drug/molecule of choice)

k

 Target ID

k

 Toxicity ID

k

 Pathway analysis

38

BioTOPics 44 | May 2012 

BioTOP-Report

Biochrom AG

Biochrom AG is a company dedicated to 

be a primary supplier of cell culture 

media and quality animal sera. 

The company manufactures and distributes 

the full range of products related to mam-

malian cell culturing technique: standard 

cell culture media, complete media tailored 

for particular cell types and cell lines, cus-

tom formulations, and animal sera, such as 

Fetal Bovine Serum (FBS). All sera are pre-

screened prior to acceptance; only those lots 

that meet strict quality control requirements 

are accepted for further processing and sub-

sequent sale to customers. Serum products 

are tested for sterility, adventi 

tious viral 

agents, physico-chemical parameters, and 

biological performance. The manufacturing 

processes are de 

signed for the specific 

needs of customers engaged in biotechno-

logical research, development, and biophar-

maceutical production. Biochrom AG spe-

cializes in meeting customers‘ specifications 

and regulatory concerns, to facilitate the 

manufacture of custom media consistent 

with Good Manufacturing Practice (GMP). 

The media are produced in a strictly con-

trolled environment; chemicals used con-

form, where applicable, to grade standards 

of European Pharmacopoeia and US Pharma-

copoeia. Biochrom AG produces lot sizes of 

sterile industrial buffers up to 4,000 litres, 

sterile media up to 2,000 litres, powder 

media up to 20,000 litres and customized 

sizes in smallest quantities. 

Biochrom AG and TPP Techno Plastic 

Products AG (Switzerland) are exclusive 

partners for the sale of TPP products for 

cell culture and general laboratory equip-

ment in Germany.

Address

Biochrom AG

Leonorenstraße 2-6

12247 Berlin · Germany

Phone [phone]

Fax 

[phone]

[e-mail]

www.biochrom.de

---